Short communicationImmunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008–2009 conventional influenza vaccine
Introduction
The emergence of swine-origin influenza A (H1N1) virus (S-OIV) [1] as a global epidemic [2] is due in part to differences between the hemagglutinin (HA) sequence of the S-OIV and conventional influenza vaccine (CIV) strains and the susceptibility of most human populations to this new strain of influenza. The differences between the hemagglutinin (HA) sequence of the S-OIV and the CIV vaccine strains became clear when individuals vaccinated against H1N1 viral strains, by CIV, failed to produce cross-reactive antibodies to the new H1N1 influenza [3]. This lack of cross-reactivity suggested that the existing vaccine might not provide effective cross-protection, setting up a “perfect storm” in terms of potential for widespread disease and significant economic impact. Compounding this concern was the fact that that novel S-OIV H1N1 is resistant to amantadine and rimantadine [4]. Resistance to the two remaining licensed antivirals, oseltamivir and zanamivir, following potential spread of the H1N1 epidemic in the southern hemisphere, has been an additional concern raised by the WHO and the CDC [5].
The 2008–2009 seasonal CIV was composed from the HA and NA proteins of three types of viruses: A/Brisbane/59/2007 H1N1, A/Brisbane/10/2007 H3N2 and B/Florida/4/2006. HA and NA from these three viruses were also used to develop the southern hemisphere influenza vaccine for 2008–2009. More than 130 million individuals in the United States have had access to the current vaccine and more than 1 billion doses were manufactured for distribution worldwide, with an estimated 500 million doses used [6].
The 2008–2009 seasonal CIV contained an H1N1 virus (A/Brisbane/59/2007). Novel S-OIV A/California/04/09 shares only 72–73% amino acid identity [7]. In contrast, the amino acid sequence identity in the HA portion among seasonal vaccine strains (2007–2008 and 2008–2009) is 97% and 98%, respectively. The amino acid sequence divergence between HA-H1 of A/California/04/09 and HA-H1 of A/Brisbane/59/2007 probably contributes to the lack of antibody cross-reactivity detected among individuals immunized with 2008–2009 CIV [3]. While overall HA and NA sequence changes are of great significance in terms of antibody response, immunological differences are also expressed on the level of T-cell epitopes, short peptide sequences recognized by T cells in the context of HLA molecules.
T-cell responses to conserved epitopes may be particularly important when new strains of influenza emerge. In mice and in humans, memory T cells to conserved epitopes have been shown to confer protection to heterotypic infection [8], [9]. The activation of Th cells is also critically important to the magnitude, quality and kinetics of antibody response [10]. In the absence of functional (memory) CD4+ T cells, studies in mice have shown that the rate of viral clearance upon secondary infection slows considerably, beyond the degree seen in the primary response [11], [12], [13]. Also in mice, cross-reactive memory T-helper cells have been shown to contribute to cross-strain antibody responses [14]. In human populations, cross-reactive T-cell responses have been demonstrated between circulating strains of influenza and epidemic strains (such as H5N1) in the absence of cross-reactive antibodies [15]. Both cross-reactive CTL and T helper cells have been identified by a number of investigators [16], [17].
A number of mechanisms could contribute to the relative lack of severe disease among older adults in areas where pandemic S-OIV is circulating. One potential explanation for protection against severe disease in the absence of cross-reactive antibodies might be the presence of cross-reactive T-cell response. Therefore, we decided to determine whether cross-conserved T-cell epitopes might be present in the novel A/California/04/09 sequence. So as to get the most immediate estimate of the potential for the existing CIV to protect against the emerging S-OIV, we examined the protein sequences of S-OIV and CIV 2008–2009 in silico, using well validated immunoinformatics tools. Herein, we describe a set of cross-reactive T-cell epitopes that are relatively well conserved between the novel S-OIV and the existing seasonal influenza vaccine strains. We provide a list of potential cross-reactive T-cell epitopes (and epitopes unique to the CIV and epidemic strains) that may be synthesized and used to confirm cross-reactivity between CIV and the epidemic strain in vitro, using peripheral white blood cells (PBMC) from exposed and vaccinated donors.
The overall average predictive efficacy of a number of epitope mapping algorithms, considering a range of viral and bacterial pathogens, has been shown to be as high as 93% for Class II epitopes and higher for Class I epitopes [18], [19]. As shown here, many of the conserved influenza epitopes defined by our tools have been previously published. Thus, computationally identified cross-reactive epitopes are a good starting point for further immunological and immunoprophylactic studies. We expect that the epitopes described will be confirmed in standard in vitro assays and that they might also be useful for the development of a novel epitope-based “cross-strain” influenza vaccine. Production of such a vaccine may be more rapid and efficient than egg- or cell culture-based vaccines in the context of an emerging epidemic.
Section snippets
Epitope mapping
EpiMatrix, a T-cell epitope mapping algorithm developed by the principal scientists at EpiVax, screens protein sequences for 9–10 amino acid long peptide segments predicted to bind to one or more MHC alleles [20], [21]. EpiMatrix uses the pocket profile method for epitope prediction, which was first described by Sturniolo and Hammer in 1999 [22]. For reasons of efficiency and simplicity, predictions are limited to the eight most common HLA Class II alleles and six “supertype” HLA Class I
HA and NA sequence conservation
We aligned the full-length HA and NA sequences of novel S-OIV and those contained in the 2008–2009 CIV strains. We find that the amino acid sequence of A/California/04/2009 H1N1 HA is 79.5% conserved in A/Brisbane/59/2007 H1N1, 42.4% conserved in A/Brisbane/10/2007 H3N2, and 30.9% conserved in B/Florida/4/2006. A/California/04/2009 H1N1 NA is 80.6% conserved in A/Brisbane/59/2007 H1N1, 44.2% conserved in A/Brisbane/10/2007 H3N2, and 32.0% conserved in B/Florida/4/2006. We also considered
Discussion
Early reports suggested that S-OIV may be more virulent among younger individuals; greater than 35% of cases have been identified among individuals age 19–49. Antibody responses resulting from previous vaccination of children with any of four seasonal trivalent, inactivated influenza vaccines (CIV) or with live, attenuated influenza vaccine (LAIV) are not cross-reactive with the novel influenza A (H1N1) virus [3]. A slightly higher prevalence of cross-reactive antibodies was found among
References (74)
- et al.
Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice
Vaccine
(2007) - et al.
Prediction of well-conserved HIV-1 ligands using a Matrix-based Algorithm, EpiMatrix
Vaccine
(1998) - et al.
Developing an epitope-driven tuberculosis (TB) vaccine
Vaccine
(2005) - et al.
Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics
Clin Immunol
(2009) - et al.
Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences
Vaccine
(1995) - et al.
Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine
Vaccine
(2007) - et al.
Efficacy of novel plasmid DNA encoding vaccinia antigens in improving current smallpox vaccination strategy
Vaccine
(2006) - et al.
Identification of immunogenic HLA-B7 “Achilles’ heel” epitopes within highly conserved regions of HIV
Vaccine
(2008) - et al.
From genome to vaccine—new immunoinformatics tools for vaccine design
Methods
(2004) - et al.
HLA supertypes and supermotifs: a functional perspective on HLA polymorphism
Curr Opin Immunol
(1998)